Lonza Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Lonza key operating metrics including Large-Molecule Clinical Development Programs (Biologics), environmental, and social and governance score (ESG).

Large-Molecule Clinical Development Programs (Biologics)

600

16.5%

FY, 2022

Clinical Small-Molecule Programs (Small-Molecule Businesses)

225

15.1%

FY, 2022

Countries

6.7%

FY, 2022

Operating Metrics

Metrics	FY, 2020	FY, 2021	FY, 2022
Large-Molecule Clinical Development Programs (Biologics)	420	515	600
Clinical Small-Molecule Programs (Small-Molecule Businesses)	400	265	225
Countries	32	30	28
Brands	792	275
Customers (Specialty Ingredients)	5.8K
Clinical Development Programs (Pharma and Biotech)	820	1K	1K
Commercial Medicines Supplied (Pharma and Biotech)	245	245	190
Commercial Small-Molecule Programs (Small-Molecule Businesses)	200	195	135
Capsules Produced (Pharma and Biotech)	230B	250B	260B
Customers (Specialty Chemical Services)	1.3K
Customers (Microbial Control Solutions)	4.7K
Trademarks and Trademark Applications	5.3K	2.6K	2.6K
Commercial Large-Molecule Medicines (Biologics)	45	50	55

50-59 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub